Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations

Lung. 2017 Aug;195(4):397-401. doi: 10.1007/s00408-017-0024-3. Epub 2017 Jun 16.


Cystic fibrosis is a complex genetic disease hallmarked by repetitive infectious exacerbations that leads to destruction of airway architecture, acute on chronic inflammatory changes, and deterioration in lung function. Predicting an exacerbation may help preempt some of these changes by the initiation of swift antibiotic and anti-inflammatory therapy. A search for biomarkers that could predict exacerbations or help guide duration of antibiotic therapy is being aggressively sought. In this review, we discuss the most recent and promising biomarkers that hopefully will assist in the future management of the CF patient.

Keywords: Biomarkers; Cystic fibrosis; Cystic fibrosis pulmonary exacerbation.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Biomarkers / blood
  • Biomarkers / metabolism*
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / immunology
  • Cystic Fibrosis / metabolism*
  • Cystic Fibrosis / microbiology
  • Disease Progression
  • Genetic Markers
  • Humans
  • Pneumonia / drug therapy
  • Pneumonia / immunology
  • Pneumonia / metabolism*
  • Pneumonia / microbiology
  • Predictive Value of Tests
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / metabolism*
  • Respiratory Tract Infections / microbiology
  • Treatment Outcome


  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Biomarkers
  • Genetic Markers